Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transcept Aims To Refile Intermezzo Insomnia NDA In Late Q4 With Highway Driving Data

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approved a resubmission plan that responds to concerns about inadvertent re-dosing and next-day driving impairment raised in an October "complete response" letter.

You may also be interested in...



Approval Delays For Transcept's Insomnia Drug Come At A Price; Milestone Payments At Stake

Transcept expects Purdue to pay a significantly lower approval milestone payment for Intermezzo given regulatory delays.

Approval Delays For Transcept's Insomnia Drug Come At A Price; Milestone Payments At Stake

Transcept expects Purdue to pay a significantly lower approval milestone payment for Intermezzo given regulatory delays.

Medication Errors: FDA Renews Focus On Drug Packaging As Part Of Prevention Campaign

June workshop is first step in development of a guidance addressing what drug developers can do to reduce mistakes.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel